IL148180A0 - Isomeric fused pyrrolocarbazoles and isoindolones - Google Patents

Isomeric fused pyrrolocarbazoles and isoindolones

Info

Publication number
IL148180A0
IL148180A0 IL14818000A IL14818000A IL148180A0 IL 148180 A0 IL148180 A0 IL 148180A0 IL 14818000 A IL14818000 A IL 14818000A IL 14818000 A IL14818000 A IL 14818000A IL 148180 A0 IL148180 A0 IL 148180A0
Authority
IL
Israel
Prior art keywords
isoindolones
fused pyrrolocarbazoles
isomeric fused
directed
same
Prior art date
Application number
IL14818000A
Other languages
English (en)
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of IL148180A0 publication Critical patent/IL148180A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
IL14818000A 1999-08-20 2000-08-18 Isomeric fused pyrrolocarbazoles and isoindolones IL148180A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15036799P 1999-08-20 1999-08-20
US09/640,825 US6399780B1 (en) 1999-08-20 2000-08-17 Isomeric fused pyrrolocarbazoles and isoindolones
PCT/US2000/022724 WO2001014380A1 (en) 1999-08-20 2000-08-18 Isomeric fused pyrrolocarbazoles and isoindolones

Publications (1)

Publication Number Publication Date
IL148180A0 true IL148180A0 (en) 2002-09-12

Family

ID=26847579

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14818000A IL148180A0 (en) 1999-08-20 2000-08-18 Isomeric fused pyrrolocarbazoles and isoindolones
IL148180A IL148180A (en) 1999-08-20 2002-02-14 Pyrolocarbazoles and isoindulones are combined isomers and pharmaceuticals containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148180A IL148180A (en) 1999-08-20 2002-02-14 Pyrolocarbazoles and isoindulones are combined isomers and pharmaceuticals containing them

Country Status (26)

Country Link
US (4) US6399780B1 (pt)
EP (1) EP1206473B1 (pt)
JP (1) JP4776842B2 (pt)
KR (1) KR100756686B1 (pt)
CN (1) CN1370173A (pt)
AT (1) ATE280172T1 (pt)
AU (1) AU776475C (pt)
BG (1) BG65545B1 (pt)
BR (1) BR0013811A (pt)
CA (1) CA2381885C (pt)
CZ (1) CZ2002616A3 (pt)
DE (1) DE60015153T2 (pt)
EA (1) EA005920B1 (pt)
ES (1) ES2230140T3 (pt)
HK (1) HK1046904B (pt)
HU (1) HUP0202758A3 (pt)
IL (2) IL148180A0 (pt)
IS (1) IS2186B (pt)
MX (1) MXPA02001789A (pt)
NO (1) NO323375B1 (pt)
NZ (1) NZ517174A (pt)
PL (1) PL354180A1 (pt)
PT (1) PT1206473E (pt)
SK (1) SK286805B6 (pt)
TR (1) TR200200474T2 (pt)
WO (1) WO2001014380A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
ES2307780T3 (es) * 2001-09-21 2008-12-01 Smithkline Beecham Corporation Compuestos quimicos.
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
BR0315164A (pt) 2002-10-08 2005-08-23 Rinat Neuroscience Corp Métodos para tratar dor pós-cirúrgica administrando um antagonista de fator de crescimento nervoso e composições contendo o mesmo
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
SI1575517T1 (sl) 2002-12-24 2012-06-29 Rinat Neuroscience Corp Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
ATE491444T1 (de) 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
ES2338344T3 (es) * 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
EP1804818A4 (en) * 2004-09-17 2009-07-22 Ford Henry Health System METHODS AND COMPOSITIONS FOR THE USE OF ANGIOGENESIS INHIBITORS IN THE PREVENTION AND / OR CONTROL OF EPILEPSY
SI1846394T1 (sl) 2005-02-04 2012-06-29 Astrazeneca Ab Pirazolilaminopiridinski derivati uporabni kot kinazni inhibitorji
ATE473975T1 (de) * 2005-02-16 2010-07-15 Astrazeneca Ab Chemische verbindungen
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU2006307657B2 (en) * 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP2009005A4 (en) 2006-04-19 2010-06-02 Astellas Pharma Inc AZOLECARBOXAMIDE DERIVATIVE
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2049535A1 (en) * 2006-08-02 2009-04-22 Takeda Pharmaceutical Company Limited Alpha-carboline derivatives and methods for preparation thereof
US8362066B2 (en) * 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
US8889271B2 (en) 2006-11-26 2014-11-18 Duksan High Metal Co., Ltd. Compound containing a 5-membered heterocycle and organic light-emitting diode using same, and terminal for same
JP2010524911A (ja) * 2007-04-18 2010-07-22 アストラゼネカ アクチボラグ ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008135786A1 (en) * 2007-05-04 2008-11-13 Astrazeneca Ab Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
PL2206707T3 (pl) 2007-10-24 2015-01-30 Astellas Pharma Inc Związek azolokarboksamidowy lub jego sól
US8426673B2 (en) 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
JP2011522870A (ja) * 2008-06-11 2011-08-04 アストラゼネカ アクチボラグ 癌および骨髄増殖性障害の処置に有用な三環式２，４−ジアミノ−ｌ，３，５−トリアジン誘導体
CN102227422A (zh) * 2008-09-30 2011-10-26 阿斯利康(瑞典)有限公司 杂环jak激酶抑制剂
CN103965204B (zh) 2008-11-19 2016-09-07 赛福伦公司 吲唑并[5,4-a]吡咯并[3,4-c]咔唑化合物的新形式
CN102482279B (zh) * 2009-03-30 2015-08-12 德山新勒克斯 有机电子装置及其化合物与终端机
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
KR101497122B1 (ko) * 2011-08-09 2015-03-06 덕산네오룩스 주식회사 2개 이상의 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
KR101478884B1 (ko) 2012-12-24 2015-01-05 충남대학교산학협력단 비스인돌일말레이미드계 화합물 및 이의 제조방법
MX2020004536A (es) 2017-11-23 2020-08-03 Biomed X Gmbh Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
FR2631199B1 (fr) 1988-05-09 1991-03-15 Centre Nat Rech Scient Reacteur a plasma
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
JP3344586B2 (ja) 1993-05-28 2002-11-11 セファロン，インコーポレイテッド インドロカルバゾール誘導体を含有する前立腺病理疾患の治療剤
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
GB9416467D0 (en) * 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
NZ323571A (en) 1995-11-20 1998-12-23 Lilly Co Eli Protein kinase c inhibitor
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
AU710669B2 (en) 1996-08-22 1999-09-23 Bristol-Myers Squibb Company Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
IS2186B (is) 2006-12-15
PT1206473E (pt) 2005-01-31
US20050107458A1 (en) 2005-05-19
WO2001014380A1 (en) 2001-03-01
MXPA02001789A (es) 2003-07-14
AU6647100A (en) 2001-03-19
US7291732B2 (en) 2007-11-06
TR200200474T2 (tr) 2002-06-21
US20020147341A1 (en) 2002-10-10
US6635669B2 (en) 2003-10-21
IL148180A (en) 2008-04-13
HUP0202758A2 (hu) 2002-12-28
CA2381885A1 (en) 2001-03-01
BG106423A (en) 2002-09-30
HUP0202758A3 (en) 2004-12-28
NO20020809D0 (no) 2002-02-19
JP4776842B2 (ja) 2011-09-21
ES2230140T3 (es) 2005-05-01
US20030216419A1 (en) 2003-11-20
US6872746B2 (en) 2005-03-29
NZ517174A (en) 2003-09-26
KR100756686B1 (ko) 2007-09-07
PL354180A1 (en) 2003-12-29
NO20020809L (no) 2002-02-20
AU776475B2 (en) 2004-09-09
SK286805B6 (sk) 2009-05-07
AU776475C (en) 2005-04-07
HK1046904B (zh) 2005-05-06
EP1206473A1 (en) 2002-05-22
BG65545B1 (bg) 2008-11-28
BR0013811A (pt) 2002-07-23
EA200200271A1 (ru) 2002-08-29
DE60015153D1 (de) 2004-11-25
SK2462002A3 (en) 2002-12-03
EA005920B1 (ru) 2005-08-25
US6399780B1 (en) 2002-06-04
DE60015153T2 (de) 2006-02-09
JP2003507480A (ja) 2003-02-25
IS6266A (is) 2002-02-12
KR20020038730A (ko) 2002-05-23
CA2381885C (en) 2009-10-27
CN1370173A (zh) 2002-09-18
EP1206473B1 (en) 2004-10-20
HK1046904A1 (en) 2003-01-30
ATE280172T1 (de) 2004-11-15
NO323375B1 (no) 2007-04-16
CZ2002616A3 (cs) 2003-04-16

Similar Documents

Publication Publication Date Title
HK1046904A1 (en) Isomeric fused pyrrolocarbazoles and isoindolones.
MXPA02004415A (es) Pirazolonas sustituidas con heterociclicas.
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
HK1020058A1 (en) Bicyclic pyrimidine derivatives and their use as anti-coagulants
TR200101567T2 (tr) Yeni triazolo(4.5-D)pirimidin bileşimleri.
BG66103B1 (bg) Кондензирани пиролокарбазоли
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
AU7743001A (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
HK1032746A1 (en) Bridged indenopyrrolocarbazoles.
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
MXPA01008347A (es) Compuestos quimicos.
YU62504A (sh) Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
EE200200326A (et) Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ZA200005110B (en) Process for preparing intermediates.
ES8602676A1 (es) Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina.
IL129727A0 (en) 1-(3-Aminoindazol-5-YL)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
AP1579A (en) Novel 17-Halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same.
AU7079300A (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed